Tagged with Alvotech

An ‘Analytical Dynamo’ Poised for More Biosimilars Success

Spain An ‘Analytical Dynamo’ Poised for More Biosimilars Success

Spain Its unorthodox name reflecting a somewhat unconventional approach, mAbxience has achieved some significant milestones in its short history, including becoming the only privately-owned company in the world with less than 500 people to have launched a monoclonal antibody biosimilar. “This is not usually a small company game, and mAbxience did…

PharmaBoardroom’s Top 10 Most Read Interviews of 2021 (So Far)

Global PharmaBoardroom’s Top 10 Most Read Interviews of 2021 (So Far)

Global PharmaBoardroom has spread its wings far and wide in 2021 (albeit digitally!), from well covered markets such as Singapore and Switzerland to new frontiers like Saudi Arabia. Our interviewees have ranged from regional Big Pharma and medtech general managers, to the CEOs of important local players, and the heads of…

China China: Yangtze River Pharmaceutical Group (YRPG) in Profile

China One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province, part of the Yangtze River Delta, where the Yangtze River feeds into the East China Sea. Founded initially in 1971,…

Alvotech’s Four Traits for Biosimilars Success

Switzerland Alvotech’s Four Traits for Biosimilars Success

Switzerland Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with biosimilar portfolios. Chief Commercial Officer Anil Okay, who sits in Switzerland, explains the four company traits that he believes will…

Anil Okay – General Manager, Adalvo & Chief Commercial Officer, Alvotech

Switzerland Anil Okay – General Manager, Adalvo & Chief Commercial Officer, Alvotech

Switzerland CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players also present in the biosimilars space. We position ourselves as a pure play, differentiated, fully vertically integrated biosimilars development…

Chinese Pharma Share Price Hit; Pfizer-LianBio Linkup; Novo’s New Chatbot

China Chinese Pharma Share Price Hit; Pfizer-LianBio Linkup; Novo’s New Chatbot

China The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from western rivals, a new Pfizer-LianBio agreement, and Thermo Fisher’s new pharma services facility. China pharma shares fall as western rivals lead in vaccine trials https://www.ft.com/content/c4c8453e-39f6-4aac-83a3-7d16a3f4fa4b…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page